1 BTC
=
- USD
Mind Medicine (MindMed) Inc. Common Shares
As of May 30, 2026 at 24:05 UTC
Chart
About Mind Medicine (MindMed) Inc. Common Shares
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Market Statistics
Trading Metrics
How to Buy MNMD
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy MNMD
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesMindMed reported strong progress in phase 3 clinical trials for MM120 ODT, targeting generalized anxiety disorder and major depressive disorder. The company maintains a robust cash position of $237.9 million, sufficient to fund operations through 2027, and is preparing for potential market entry.
MindMed, a clinical-stage biotech company developing brain health medications based on psychedelic compounds, faces regulatory challenges but shows potential as public support for medical psychedelic research grows.
Mind Medicine's stock is surging after Robert F. Kennedy Jr. was confirmed as the new U.S. Health and Human Services secretary. Kennedy has previously voiced support for psychedelics as therapeutic treatments, which could benefit Mind Medicine's drug development efforts.
The 5-HT2 agonist pipeline is robust, with over 20 pharmaceutical companies actively developing 22+ pipeline drugs. Advancements in precision medicine and personalized approaches are driving the market, enabling selective targeting of receptor subtypes and improving safety and efficacy.
A Minnesota task force has urged the decriminalization of psilocybin mushrooms and supported greater funding for psychedelics research. This could benefit MindMed, a clinical-stage biotech company focused on potential medical applications for psychedelics.